Unicycive Therapeutics (UNCY) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

UNCY · Stock Price

USD 7.86+2.36 (+42.91%)

Market Cap: $210.9M

Historical price data

Overview

Unicycive Therapeutics is an agile, clinical-stage biotech focused exclusively on developing innovative therapies for kidney disease. Its strategy centers on in-licensing or acquiring promising, overlooked assets and advancing them with speed and operational efficiency. The company's lead asset, Oxylanthanum Carbonate (OLC), has an FDA PDUFA date of June 29, 2026, positioning it for a potential near-term commercial launch in the multi-billion dollar hyperphosphatemia market.

Kidney Disease

Technology Platform

An agile, asset-centric development model focused on in-licensing or acquiring overlooked kidney disease therapies and advancing them with operational efficiency, rather than a traditional discovery platform.

Opportunities

OLC addresses a multi-billion dollar hyperphosphatemia market with a potentially best-in-class adherence profile.

UNI-494 targets the vast, untapped Acute Kidney Injury market, which has no approved pharmacologic therapies, representing a groundbreaking first-in-class opportunity.

Risk Factors

Key risks include regulatory rejection or delay for OLC (PDUFA date June 29, 2026), intense commercial competition from generic phosphate binders, the need for dilutive financing, and the high clinical failure risk associated with the early-stage AKI program.

Competitive Landscape

OLC competes in a crowded hyperphosphatemia market dominated by generics (sevelamer, lanthanum) and newer agents like tenapanor, requiring it to prove superior adherence and value. UNI-494's primary competition is the lack of any approved AKI drug, though it faces the historical challenge of high failure rates in AKI clinical development.

More companies in Small Molecule Drugs →More companies in United States →